Biogen EPS misses, guides up
at Investor's Business Daily - Wed Apr 23, 5:49PM CDT
The biotech's Q1 EPS jumped 25% to $2.47, but missed views by 9 cents. Revenue rose 50.5% to $2.13 bil, above views for $2 bil. U.S. sales of MS drug Tecfidera were $460 mil vs. views of $413 mil. Nearly all individual product sales beat consensus....
Biogen Q1, Guidance Strong, But Stock Slips
at Investor's Business Daily - Wed Apr 23, 5:46PM CDT
Big-cap biotech Biogen Idec reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock rose just a fraction as biotechs had a bad day and Biogen revealed it's being probed by authorities. Biogen (BIIB)...
Why Biogen (BIIB) Stock Is Down Today
at The Street - Wed Apr 23, 12:55PM CDT
Biogen (BIIB) shares fall as Biotech ETF as takes a hit in trading today
Biogen's Q1 Earnings Soar Y/Y on Tecfidera Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 12:40PM CDT
Although Biogen (BIIB) missed earnings estimates, revenues surpassed expectations easily. The company also raised its guidance.
Interesting BIIB Put And Call Options For June 21st
at The Street - Wed Apr 23, 10:05AM CDT
Investors in Biogen Idec Inc saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options chain for the new June 21st contracts and identified one put...
Biogen Q1 Sales Beat Street, Guidance Strong
at Investor's Business Daily - Wed Apr 23, 9:11AM CDT
Big-cap biotech Biogen Idec (BIIB) reported solid Q1 revenue early Wednesday and guided 2014 above Wall Street's expectations, but the stock was down more than 1% in early trading in the stock market today. Biogen said revenue rose 50.5% over the...
Amgen's Q1 Earnings Decline Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:40AM CDT
Amgen's first quarter results were disappointing with most of the products recording a sequential decline in sales.
Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 8:39AM CDT
Revance Therapeutics, Inc. was a big mover last session, as its shares rose nearly 26% on the day.
Alliance Fiber Optic, Talisman Energy, Gilead Sciences, Biogen Idec and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Apr 23, 8:30AM CDT
Zacks Equity Research highlights Alliance Fiber Optic (Nasdaq:AFOP-Free Report) as the Bull of the Day and Talisman Energy (NYSE:TLM-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onGilead Sciences Inc. (Nasdaq:GILD-Free Report), Biogen Idec Inc. (Nasdaq:BIIB-Free Report) and Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report).
Why Biogen Idec (BIIB) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:43AM CDT
Biogen Idec (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. The company looks set to produce a positive earnings surprise and outperform analyst expectations.
Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise
Business Wire - Wed Apr 23, 6:02AM CDT
--Neurology Pipeline Expands through Alzheimer's Disease Collaboration with Eisai
'Fast Money' Recap: Riding the Momentum
at The Street - Wed Apr 23, 4:00AM CDT
The trading panel looked at Amazon, Netflix and biotech stocks.
A Drill Can Help Identify Right Time To Sell Leaders
at Investor's Business Daily - Tue Apr 22, 5:11PM CDT
When leading stocks fall, you need to read the situation impartially. However, if you have a position in a top stock from a top group, emotions can cloud judgment. You might sell in fear, or you might hold firm in stubbornness. A drill is the best...
Is Biogen (BIIB) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 5:05PM CDT
Biogen has an earnings ESP of +8.14% with Zacks Rank #1 (Strong Buy).
Stocks Rise In Higher Volume; Gilead Up After Hours
at Investor's Business Daily - Tue Apr 22, 4:15PM CDT
Stocks rose in higher volume Tuesday, with the Nasdaq and S&P 500 notching their sixth straight gains amid a flurry of buyout activity in the drugs industry. The Nasdaq rose 1%, while the S&P 500 and the Dow Jones industrial average each rose 0.4%....
Sarepta Soars on Eteplirsen Submission Plans - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 3:45PM CDT
Sarepta shares soared over 39% after the company announced it would submit a NDA for eteplirsen by year end.
Biotech Earnings Preview
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 1:00PM CDT
It's Fools' favorite time of the year: earnings season. In the video below, senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss a few biotechs that will release first quarter earnings shortly. Gilead Sciences...
Keep an Eye on these 3 Biotech Stocks - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 10:49AM CDT
This sell-off was more due to a change in sentiment rather than a shift in industry fundamentals.
Alexion Likely to Keep Earnings Streak Alive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 10:00AM CDT
Alexion is set to report first quarter 2014 results before the opening bell on Apr 24.
Insider Trading Alert - BIIB, JAZZ And KWK Traded By Insiders
at The Street - Tue Apr 22, 9:15AM CDT
Stocks with insider trader activity include BIIB, JAZZ and KWK